{
  "risk_score_0_to_1": 0.68,
  "confidence_0_to_1": 0.92,
  "dominant_mechanisms": [
    {"mechanism": "mitochondrial_dysfunction", "score_0_to_1": 0.95},
    {"mechanism": "reactive_metabolite_formation", "score_0_to_1": 0.75},
    {"mechanism": "cholestasis_bsep_inhibition", "score_0_to_1": 0.30},
    {"mechanism": "immune_mediated_injury", "score_0_to_1": 0.25},
    {"mechanism": "oxidative_stress", "score_0_to_1": 0.85}
  ],
  "time_to_onset": "subacute_weeks_to_months",
  "dose_dependence": "dose_dependent",
  "reversibility": "variable_some_irreversible",
  "uncertainties": [
    "Genetic screening for mitochondrial disorders not standardized before valproate initiation",
    "POLG mutations confer extreme risk but frequency and penetrance vary by population",
    "Carnitine depletion contribution to toxicity versus marker of mitochondrial dysfunction debated",
    "Why young children (<2 years) and polytherapy increase risk not fully mechanistically explained"
  ],
  "citations": [
    "Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67(1):101-154.",
    "Stewart JD, et al. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat Rev Genet. 2015;16(9):530-542.",
    "NjÃ¥lsson R, et al. Valproate-induced liver injury: two case reports and review of the literature. Scand J Gastroenterol. 2003;38(11):1182-1186."
  ]
}